Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Messengers: fibroblast growth factor 15/19
Raffaella Maria Gadaleta, Antonio Moschetta
Nature Metabolism (2019) Vol. 1, Iss. 6, pp. 588-594
Closed Access | Times Cited: 95

Showing 26-50 of 95 citing articles:

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Haoyu Tian, Shuairan Zhang, Ying Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4583-4583
Open Access | Times Cited: 21
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease
Michele Biagioli, Silvia Marchianò, Cristina Di Giorgio, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115900-115900
Open Access | Times Cited: 20
FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells
Jingchun Wang, Huakan Zhao, Lu Zheng, et al.
Theranostics (2021) Vol. 11, Iss. 10, pp. 5045-5060
Open Access | Times Cited: 38
Ileal FXR-FGF15/19 signaling activation improves skeletal muscle loss in aged mice
Yixuan Qiu, Jiaming Yu, Xueying Ji, et al.
Mechanisms of Ageing and Development (2022) Vol. 202, pp. 111630-111630
Closed Access | Times Cited: 25
Metabolic Messengers: fibroblast growth factor 1
Emanuel Gasser, Gencer Sancar, Michael Downes, et al.
Nature Metabolism (2022) Vol. 4, Iss. 6, pp. 663-671
Open Access | Times Cited: 23
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Zhenhua Yang, Awang Danzeng, Qiumeng Liu, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 113-126
Open Access | Times Cited: 16
Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial
Xiaotao Zhang, Ehsan Irajizad, Kristi L. Hoffman, et al.
EBioMedicine (2023) Vol. 98, pp. 104873-104873
Open Access | Times Cited: 16
Targeting gut-liver axis by dietary lignans ameliorate obesity: evidences and mechanisms
Zhongxing Chu, Zuomin Hu, Yi Luo, et al.
Critical Reviews in Food Science and Nutrition (2023), pp. 1-22
Closed Access | Times Cited: 15
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease
Qiang Ren, Ya Chen, Zongtao Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6082-6104
Closed Access | Times Cited: 13
The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease
Arno R. Bourgonje, Shixian Hu, Lieke M. Spekhorst, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 3, pp. 414-429
Open Access | Times Cited: 30
Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation
Qin He, Wenjie Huang, Danfei Liu, et al.
Theranostics (2021) Vol. 11, Iss. 12, pp. 5759-5777
Open Access | Times Cited: 29
Linking liver metabolic and vascular disease via bile acid signaling
Stefano Fiorucci, Eleonora Distrutti
Trends in Molecular Medicine (2021) Vol. 28, Iss. 1, pp. 51-66
Closed Access | Times Cited: 28
FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
Zhanchao Tao, Yue Cui, Xilong Xu, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 40
Open Access | Times Cited: 20
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments
Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, et al.
Cells (2024) Vol. 13, Iss. 19, pp. 1650-1650
Open Access | Times Cited: 4
Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress
Lintao Song, Yushu Hou, Da Xu, et al.
Cell Metabolism (2024)
Closed Access | Times Cited: 4
Schisandra chinensis lignans ameliorate hepatic inflammation and steatosis in methionine choline-deficient diet-fed mice by modulating the gut-liver axis
Li-Shan Yan, Jian-Ying Kang, Chunyu Gu, et al.
Journal of Ethnopharmacology (2025), pp. 119801-119801
Closed Access
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease
Stefano Fiorucci, Michele Biagioli, Monia Baldoni, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 10, pp. 1193-1208
Closed Access | Times Cited: 25
Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver
Raffaella Maria Gadaleta, Antonio Moschetta
Journal of Hepatology (2021) Vol. 75, Iss. 6, pp. 1440-1451
Open Access | Times Cited: 24
Minocycline-induced disruption of the intestinal FXR/FGF15 axis impairs osteogenesis in mice
Matthew D. Carson, Amy J. Warner, Jessica D. Hathaway‐Schrader, et al.
JCI Insight (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 17
FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
José Ursic‐Bedoya, Guillaume Desandré, Carine Chavey, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 2, pp. 238-250
Open Access | Times Cited: 3
Pulsatilla decoction alleviates DSS-induced UC by activating FXR-ASBT pathways to ameliorate disordered bile acids homeostasis
Ying Xiao, Ya‐qian Jia, Wenjuan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Bile acids and their receptors in hepatic immunity
Stefano Fiorucci, Silvia Marchianò, Eleonora Distrutti, et al.
Liver Research (2025)
Open Access
Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets
Yi Chu, Yang Su, Xiaodong Chen
Pharmacology & Therapeutics (2025), pp. 108844-108844
Closed Access
Mechanisms of bone regeneration repair and potential and efficacy of small molecule drugs
Ke Zhang, Hao Li, Tao Wang, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 187, pp. 118070-118070
Closed Access
Food-derived polysaccharides and anti-obesity effects through enhancing adipose thermogenesis: structure-activity relationships, mechanisms, and regulation of gut microecology
Zhenyu Wang, Qiyu Xu, Lijuan Hou, et al.
Critical Reviews in Food Science and Nutrition (2025), pp. 1-22
Open Access

Scroll to top